UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Autodigit-RAD: Towards an automation of the radon’s concentration dataflow in a new and innovative building

Journal of physics. Conference series, 2023-11, Vol.2600 (10), p.102008

2023

Volltextzugriff (PDF)

Droits humains et education sexuelle: Contexte, perceptions et pratiques

2021

Volltextzugriff (PDF)

Increasing salinity of fibrinogen solvent generates stable fibrin hydrogels for cell delivery or tissue engineering

PloS one, 2021-05, Vol.16 (5), p.e0239242-e0239242

2021

Volltextzugriff (PDF)

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

European journal of cancer (1990), 2018-05, Vol.95, p.93-101

2018

Volltextzugriff (PDF)

A next-generation liquid xenon observatory for dark matter and neutrino physics

Journal of physics. G, Nuclear and particle physics, 2023-01, Vol.50 (1), p.13001

2023

Volltextzugriff (PDF)

Atom probe tomography of secondary γ′ precipitation in a single crystal Ni-based superalloy after isothermal aging at 1100°C

Journal of alloys and compounds, 2014-10, Vol.611, p.389-394

2014

Volltextzugriff (PDF)

Philippe Sarrasin Robichaud, L’Homme-clavecin, une analogie diderotienne

Recherches sur Diderot et sur l'Encyclopédie, 2018, Vol.53 (1), p.296-299

Jacot-Grapa, Caroline

2018

Volltextzugriff (PDF)

372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database

Annals of oncology, 2024-09, Vol.35, p.S374-S375

2024

Volltextzugriff (PDF)

1818MO Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC)

Annals of oncology, 2024-09, Vol.35, p.S1078-S1079

2024

Volltextzugriff (PDF)

240P Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases

Annals of oncology, 2022-09, Vol.33, p.S647

2022

Volltextzugriff (PDF)

Spinodal Decomposition Mechanism of γ′ Precipitation in a Single Crystal Ni-Based Superalloy

Metallurgical and materials transactions. A, Physical metallurgy and materials science, 2014-10, Vol.45 (11), p.4725-4730

2014

Volltextzugriff (PDF)

P14.04 Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases. A prospective study

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii38-ii39

2021

Volltextzugriff (PDF)

Abstract P3-14-01: High-dose vitamin D supplementation for the correction of vitamin D insufficiency in patients undergoing adjuvant chemotherapy for breast cancer, a phase II multicenter study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-14-01

2019

Volltextzugriff (PDF)

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

Annals of oncology, 2023-10, Vol.34, p.S334-S335

2023

Volltextzugriff (PDF)

388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)

Annals of oncology, 2023-10, Vol.34, p.S342-S343

2023

Volltextzugriff (PDF)

250P Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database

Annals of oncology, 2022-09, Vol.33, p.S651

2022

Volltextzugriff (PDF)

231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers

Annals of oncology, 2021-09, Vol.32, p.S458-S459

2021

Volltextzugriff (PDF)

Abstract P3-14-03: Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-14-03

2019

Volltextzugriff (PDF)

Abstract P2-10-09: Clinical correlations of serum vitamin D in patients undergoing neoadjuvant systemic therapy and survival outcomes for operable breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-10-09

2018

Volltextzugriff (PDF)

Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v117-v118

2019

Volltextzugriff (PDF)

332P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v117-v118

2019

Volltextzugriff (PDF)

1425PTowards a screening test for cancer by circulating DNA analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1425P - Towards a screening test for cancer by circulating DNA analysis

Annals of oncology, 2019-10, Vol.30, p.v580-v580

2019

Volltextzugriff (PDF)

332PRibociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1 – 25 von 401

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(248)
Mit Volltextzugriff
(311)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Französisch
(288)
Englisch
(111)
Deutsch
(11)

Erscheinungsjahr

n.n

Thema

Humans
(40)
Physics
(31)
Science & Technology
(29)
Physical Sciences
(25)
Sciences Biologiques Et Medicales
(23)
Sciences Medicales
(22)
Physics, Atomic, Molecular & Chemical
(18)
Breast Cancer
(17)
Cancer Du Sein
(15)
Female
(15)
Physics, Nuclear
(15)
Male
(13)
Tumeurs
(12)
Physics, Condensed Matter
(10)
Plant Biochemistry
(10)
Plant Physiology
(10)
Aged
(9)
Atomic And Molecular Physics
(9)
Chemotherapy
(9)
Chimie
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Autodigit-RAD: Towards an automation of the radon’s concentration dataflow in a new and innovative building

Droits humains et education sexuelle: Contexte, perceptions et pratiques

Increasing salinity of fibrinogen solvent generates stable fibrin hydrogels for cell delivery or tissue engineering

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

A next-generation liquid xenon observatory for dark matter and neutrino physics

Atom probe tomography of secondary γ′ precipitation in a single crystal Ni-based superalloy after isothermal aging at 1100°C

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study

Philippe Sarrasin Robichaud, L’Homme-clavecin, une analogie diderotienne

372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database

1818MO Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC)

240P Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases

Spinodal Decomposition Mechanism of γ′ Precipitation in a Single Crystal Ni-Based Superalloy

P14.04 Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases. A prospective study

Abstract P3-14-01: High-dose vitamin D supplementation for the correction of vitamin D insufficiency in patients undergoing adjuvant chemotherapy for breast cancer, a phase II multicenter study

376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)

250P Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database

231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers

Abstract P3-14-03: Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

Abstract P2-10-09: Clinical correlations of serum vitamin D in patients undergoing neoadjuvant systemic therapy and survival outcomes for operable breast cancer

Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

332P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

1425PTowards a screening test for cancer by circulating DNA analysis

1425P - Towards a screening test for cancer by circulating DNA analysis

332PRibociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Aktive Filter

Suchergebnisse filtern